Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

In this article:

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why This 1 Growth Stock Should Be On Your Watchlist

Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

HealthEquity (HQY)

Draper, UT-headquartered HealthEquity provides integrated solutions for health-care account management, health reimbursement arrangement and flexible spending accounts for health plans, insurance companies and third-party administrators in the United States.

HQY boasts a Growth Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 60.3% year-over-year for 2024, while Wall Street anticipates its top line to improve by 15.5%.

Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.03 to $2.18 per share. HQY boasts an average earnings surprise of 16.5%.

HealthEquity is also cash rich. The company has generated cash flow growth of 36%, and is expected to report cash flow expansion of 9.5% in 2024.

Investors should take the time to consider HQY for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

HealthEquity, Inc. (HQY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement